Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808442 · ClinicalTrials.gov registry record · Phase 1
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
A Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia and Refractory B-cell Acute Lymphoblastic Leukemia, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 6
- Study locations
NCT02808442 is a Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia and Refractory B-cell Acute Lymphoblastic Leukemia that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 13 participants. The trial reports 6 study locations across 4 states.
The verdict
NCT02808442, a Phase 1 study of Relapsed B-Cell Acute Lymphoblastic Leukemia and Refractory B-cell Acute Lymphoblastic Leukemia, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
Conditions Studied
Interventions
- BIOLOGICAL UCART19
Study Locations (6)
Other
- Hôpital Robert-Debré - Paris
- Hospital San Juan De Dios - Barcelona
- UCL Great Ormond Hospital - London
California
- Children's Hospital Los Angeles - Los Angeles
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-06-03 |
| Est. Completion | 2020-11-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02808442
The ClinicalTrials.gov registry entry for NCT02808442 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Relapsed B-Cell Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which UCART19 is the first listed.
NCT02808442 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02808442 about?
NCT02808442 is a clinical study titled "Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia". This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).
What is the current status of trial NCT02808442?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2016-06-03. Estimated completion is 2020-11-04.
What conditions does trial NCT02808442 study?
This clinical trial studies the following conditions: Relapsed B-Cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT02808442?
The interventions under investigation include: UCART19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02808442?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02808442 being conducted?
This trial has 6 study locations across California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed B-Cell Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Relapsed B-Cell Acute Lymphoblastic Leukemia
All registered trials for this condition
Refractory B-cell Acute Lymphoblastic Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.